We found for
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Realising the Broader Value of Vaccines in the UK

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

The Impact of New Medicines in the NHS: 70 Years of Innovation

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Establishing a Reasonable Price for an Orphan Drug

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making

Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
